$13.80
+0.16 (+1.17%)
Open$13.70
Previous Close$13.64
Day High$14.05
Day Low$13.63
52W High$18.33
52W Low$1.54
Volume—
Avg Volume1.91M
Market Cap815.59M
P/E Ratio—
EPS$-0.82
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
+89.2% upside
Current
$13.80
$13.80
Target
$26.11
$26.11
$17.52
$26.11 avg
$31.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 93.03M | 87.17M | 93.25M |
| Net Income | -25,402,018 | -21,372,578 | -19,024,947 |
| Profit Margin | -27.3% | -24.5% | -20.4% |
| EBITDA | -33,224,495 | -30,585,289 | -30,503,356 |
| Free Cash Flow | -14,578,727 | -14,999,377 | -17,296,703 |
| Rev Growth | -8.3% | +13.0% | +19.4% |
| Debt/Equity | 0.78 | 0.63 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |